## Valentina Mercurio

## List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/6916339/valentina-mercurio-publications-by-year.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

65	1,014	17	30
papers	citations	h-index	g-index
80 ext. papers	1,454 ext. citations	<b>5.1</b> avg, IF	4.32 L-index

#	Paper	IF	Citations
65	Cardiovascular events and treatment of children with high risk medulloblastoma <i>EClinicalMedicine</i> , <b>2022</b> , 43, 101251	11.3	O
64	Echocardiographically defined haemodynamic categorization predicts prognosis in ambulatory heart failure patients treated with sacubitril/valsartan ESC Heart Failure, 2022,	3.7	1
63	Cardiovascular safety of the tyrosine kinase inhibitor nintedanib. <i>British Journal of Clinical Pharmacology</i> , <b>2021</b> , 87, 3690-3698	3.8	1
62	How can we manage the cardiac toxicity of immune checkpoint inhibitors?. <i>Expert Opinion on Drug Safety</i> , <b>2021</b> , 20, 685-694	4.1	5
61	Inflammatory Mechanisms in the Pathogenesis of Pulmonary Arterial Hypertension: Recent Advances. <i>Comprehensive Physiology</i> , <b>2021</b> , 11, 1805-1829	7.7	1
60	Non-cardiovascular comorbidities in heart failure patients and their impact on prognosis. <i>Kardiologia Polska</i> , <b>2021</b> , 79, 493-502	0.9	0
59	Assessment of right ventricular reserve utilizing exercise provocation in systemic sclerosis. <i>International Journal of Cardiovascular Imaging</i> , <b>2021</b> , 37, 2137-2147	2.5	3
58	New-Onset Cancer in the HF Population: Epidemiology, Pathophysiology, and Clinical Management. <i>Current Heart Failure Reports</i> , <b>2021</b> , 18, 191-199	2.8	1
57	Oxidative stress in anticancer therapies-related cardiac dysfunction. <i>Free Radical Biology and Medicine</i> , <b>2021</b> , 169, 410-415	7.8	1
56	Lung ultrasound as diagnostic tool for SARS-CoV-2 infection. <i>Internal and Emergency Medicine</i> , <b>2021</b> , 16, 471-476	3.7	16
55	Time-weighted lactate as a predictor of adverse outcome in acute heart failure. <i>ESC Heart Failure</i> , <b>2021</b> , 8, 539-545	3.7	4
54	Risk Reduction and Hemodynamics with Initial Combination Therapy in Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2021</b> , 203, 484-492	10.2	12
53	Essential Hypertension Worsens Left Ventricular Contractility in Systemic Sclerosis. <i>Journal of Rheumatology</i> , <b>2021</b> , 48, 1299-1306	4.1	1
52	Anthracyclines and regional myocardial damage in breast cancer patients. A multicentre study from the Working Group on Drug Cardiotoxicity and Cardioprotection, Italian Society of Cardiology (SIC). <i>European Heart Journal Cardiovascular Imaging</i> , <b>2021</b> , 22, 406-415	4.1	1
51	Cardiovascular Toxicity of Immune Checkpoint Inhibitors: Clinical Risk Factors. <i>Current Oncology Reports</i> , <b>2021</b> , 23, 13	6.3	11
50	Right ventricular function as assessed by cardiac magnetic resonance imaging-derived strain parameters compared to high-fidelity micromanometer catheter measurements. <i>Pulmonary Circulation</i> , <b>2021</b> , 11, 20458940211032529	2.7	1
49	Effect of Sacubitril-Valsartan in reducing depression in patients with advanced heart failure. <i>Journal of Affective Disorders</i> , <b>2020</b> , 272, 132-137	6.6	7

48	A comprehensive echocardiographic method for risk stratification in pulmonary arterial hypertension. <i>European Respiratory Journal</i> , <b>2020</b> , 56,	13.6	14
47	Commentary on "Functional Improvement After Outpatient Cardiac Rehabilitation in Acute Coronary Syndrome Patients is not Related to Improvement in Left Ventricular Ejection Fraction". <i>High Blood Pressure and Cardiovascular Prevention</i> , <b>2020</b> , 27, 179-181	2.9	
46	Peripheral Vascular Function in Dilated Cardiomyopathy of Different Etiology. <i>Angiology</i> , <b>2020</b> , 71, 726	-7 <u>2</u> 33	0
45	Pulmonary Hypertension Phenotypes in Systemic Sclerosis: The Right Diagnosis for the Right Treatment. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	8
44	Sacubitril/valsartan in patients listed for heart transplantation: effect on physical frailty. <i>ESC Heart Failure</i> , <b>2020</b> , 7, 757-762	3.7	16
43	Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis. <i>European Heart Journal</i> , <b>2020</b> , 41, 1733-1743	9.5	114
42	Long-term follow-up in high risk hypertensive patients with carotid dolicoarteriopathies. <i>International Angiology</i> , <b>2020</b> , 39, 24-28	2.2	О
41	Adapted recreational football small-sided games improve cardiac capacity, body composition and muscular fitness in patients with type 2 diabetes. <i>Journal of Sports Medicine and Physical Fitness</i> , <b>2020</b> , 60, 1261-1268	1.4	O
40	Comorbidities in chronic heart failure: An update from Italian Society of Cardiology (SIC) Working Group on Heart Failure. <i>European Journal of Internal Medicine</i> , <b>2020</b> , 71, 23-31	3.9	17
39	Hemodynamics and risk assessment 2 years after the initiation of upfront ambrisentan-tadalafil in pulmonary arterial hypertension. <i>Journal of Heart and Lung Transplantation</i> , <b>2020</b> , 39, 1389-1397	5.8	3
38	Ticagrelor Conditioning Effects Are Not Additive to Cardioprotection Induced by Direct NLRP3 Inflammasome Inhibition: Role of RISK, NLRP3, and Redox Cascades. <i>Oxidative Medicine and Cellular Longevity</i> , <b>2020</b> , 2020, 9219825	6.7	10
37	Redox Imbalances in Ageing and Metabolic Alterations: Implications in Cancer and Cardiac Diseases. An Overview from the Working Group of Cardiotoxicity and Cardioprotection of the Italian Society of Cardiology (SIC). <i>Antioxidants</i> , <b>2020</b> , 9,	7.1	7
36	Sex-related differences in COVID-19 lethality. <i>British Journal of Pharmacology</i> , <b>2020</b> , 177, 4375-4385	8.6	36
35	A nutraceutical combination reduces left ventricular mass in subjects with metabolic syndrome and left ventricular hypertrophy: A multicenter, randomized, double-blind, placebo-controlled trial. <i>Clinical Nutrition</i> , <b>2020</b> , 39, 1379-1384	5.9	6
34	Cancer Risk in the Heart Failure Population: Epidemiology, Mechanisms, and Clinical Implications. <i>Current Oncology Reports</i> , <b>2020</b> , 23, 7	6.3	6
33	The use of chest ultrasonography in suspected cases of COVID-19 in the emergency department. <i>Future Science OA</i> , <b>2020</b> , 7, FSO635	2.7	2
32	What Is the Cardiac Impact of Chemotherapy and Subsequent Radiotherapy in Lymphoma Patients?. <i>Antioxidants and Redox Signaling</i> , <b>2019</b> , 31, 1166-1174	8.4	11
31	Heart Failure and Cancer: Mechanisms of Old and New Cardiotoxic Drugs in Cancer Patients.  Cardiac Failure Review, <b>2019</b> , 5, 112-118	4.2	27

30	Inflammatory, Serological and Vascular Determinants of Cardiovascular Disease in Systemic Lupus Erythematosus Patients. <i>International Journal of Molecular Sciences</i> , <b>2019</b> , 20,	6.3	16
29	Efficacy of a nutraceutical combination on lipid metabolism in patients with metabolic syndrome: a multicenter, double blind, randomized, placebo controlled trial. <i>Lipids in Health and Disease</i> , <b>2019</b> , 18, 66	4.4	7
28	The novel butyrate derivative phenylalanine-butyramide protects from doxorubicin-induced cardiotoxicity. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 519-528	12.3	45
27	Influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors <b>2019</b> , 7, 53		42
26	EXPRESS: Cardiac Sympathetic Dysfunction in Pulmonary Arterial Hypertension: Lesson from Left-sided Heart Failure. <i>Pulmonary Circulation</i> , <b>2019</b> , 2045894019868620	2.7	8
25	Metabolomic Perspectives in Antiblastic Cardiotoxicity and Cardioprotection. <i>International Journal of Molecular Sciences</i> , <b>2019</b> , 20,	6.3	6
24	New Drugs, Therapeutic Strategies, and Future Direction for the Treatment of Pulmonary Arterial Hypertension. <i>Current Medicinal Chemistry</i> , <b>2019</b> , 26, 2844-2864	4.3	11
23	Molecular Mechanisms of Cardiovascular Damage Induced by Anti-HER-2 Therapies. <i>Current Clinical Pathology</i> , <b>2019</b> , 15-19	0.1	
22	Progress in Understanding, Diagnosing, and Managing Cardiac Complications of Systemic Sclerosis. Current Rheumatology Reports, <b>2019</b> , 21, 68	4.9	11
21	Pulmonary arterial hypertension and atrial arrhythmias: incidence, risk factors, and clinical impact. <i>Pulmonary Circulation</i> , <b>2018</b> , 8, 2045894018769874	2.7	20
20	Improvement in Right Ventricular Strain with Ambrisentan and Tadalafil Upfront Therapy in Scleroderma-associated Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2018</b> , 197, 388-391	10.2	24
19	Antineoplastic Drug-Induced Cardiotoxicity: A Redox Perspective. Frontiers in Physiology, 2018, 9, 167	4.6	74
18	Immune Checkpoint Inhibitors and Cardiac Toxicity: An Emerging Issue. <i>Current Medicinal Chemistry</i> , <b>2018</b> , 25, 1327-1339	4.3	69
17	Severe Aortic Valve Regurgitation in Relapsing Polychondritis. <i>Journal of Clinical Rheumatology</i> , <b>2018</b> , 24, 109-111	1.1	1
16	Pharmacovigilating cardiotoxicity of immune checkpoint inhibitors. <i>Lancet Oncology, The</i> , <b>2018</b> , 19, 154	15 <u>2</u> 1 <i>5</i> /46	5 9
15	Risk assessment in scleroderma patients with newly diagnosed pulmonary arterial hypertension: application of the ESC/ERS risk prediction model. <i>European Respiratory Journal</i> , <b>2018</b> , 52,	13.6	17
14	Right heart dysfunction: from pathophysiologic insights to therapeutic options: a translational overview. <i>Journal of Cardiovascular Medicine</i> , <b>2018</b> , 19, 613-623	1.9	4
13	Phenotyping pulmonary hypertension in systemic sclerosis: a moving target. <i>Pulmonary Circulation</i> , <b>2018</b> , 8, 2045894018785247	2.7	1

## LIST OF PUBLICATIONS

12	Poor survival in patients with scleroderma and pulmonary hypertension due to heart failure with preserved ejection fraction. <i>Pulmonary Circulation</i> , <b>2017</b> , 7, 409-420	2.7	21
11	Right ventricular longitudinal strain is diminished in systemic sclerosis compared with idiopathic pulmonary arterial hypertension. <i>European Respiratory Journal</i> , <b>2017</b> , 50,	13.6	25
10	Preventing antiblastic drug-related cardiomyopathy: old and new therapeutic strategies. <i>Journal of Cardiovascular Medicine</i> , <b>2016</b> , 17 Suppl 1, S64-75	1.9	18
9	Models of Heart Failure Based on the Cardiotoxicity of Anticancer Drugs. <i>Journal of Cardiac Failure</i> , <b>2016</b> , 22, 449-58	3.3	42
8	Serum soluble ST2 and interleukin-33 levels in patients with pulmonary arterial hypertension. <i>International Journal of Cardiology</i> , <b>2013</b> , 168, 1545-7	3.2	41
7	Effects of a nutraceutical combination on left ventricular remodeling and vasoreactivity in subjects with the metabolic syndrome. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , <b>2012</b> , 22, e13-4	4.5	3
6	Response to pulmonary vasodilator treatment in a former smoker with combined interstitial lung disease complicated by pulmonary hypertension: case report and review of the literature. <i>Heart and Lung: Journal of Acute and Critical Care</i> , <b>2012</b> , 41, 512-7	2.6	12
5	Insulin resistance: Is it time for primary prevention?. World Journal of Cardiology, 2012, 4, 1-7	2.1	19
4	A nutraceutical combination improves insulin sensitivity in patients with metabolic syndrome. <i>World Journal of Cardiology</i> , <b>2012</b> , 4, 77-83	2.1	54
3	Efficacy and safety of valsartan plus hydroclorothiazide for high blood pressure. <i>World Journal of Cardiology</i> , <b>2010</b> , 2, 125-30	2.1	1
2	Cardiovascular and metabolic effects of Berberine. World Journal of Cardiology, 2010, 2, 71-7	2.1	64
1	Sex-Related Differences in COVID-19 Lethality		2